Oligodendrogliomas Withdrawn Phase 2 Trials for Nivolumab (DB09035)

Also known as: Oligodendroglioma / [M]Oligodendroglioma NOS / Oligodendroglioma, Well-Differentiated

IndicationStatusPhase
DBCOND0032978 (Oligodendrogliomas)Withdrawn2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03014804Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in Treating Patients With Recurrent GlioblastomaTreatment